We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
- Authors
Kim, Jee Hung; Park, Hyung Soon; Heo, Su Jin; Kim, Sang Kyum; Han, Jung Woo; Shin, Kyoo-Ho; Kim, Seung Hyun; Hur, Hyuk; Kim, Kyung Sik; Choi, Young Deuk; Kim, Sunghoon; Lee, Young Han; Suh, Jin-Suck; Ahn, Joong-Bae; Chung, Hyun Cheol; Noh, Sung Hoon; Rha, Sun Young; Kim, Hyo Song
- Abstract
Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1–2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.
- Subjects
PROTEIN-tyrosine kinase inhibitors; DOCETAXEL; THERAPEUTIC use of antimetabolites; IFOSFAMIDE; METASTASIS; SARCOMA; SOFT tissue tumors; TREATMENT effectiveness; DISEASE progression; LEIOMYOSARCOMA; CONNECTIVE tissue tumors; TUMOR grading; PROGNOSIS; THERAPEUTICS
- Publication
Oncology, 2019, Vol 96, Issue 2, p59
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000492597